LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021
-Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date
-New Chief Scientific and Chief Financial Officers recently added to Executive Team
News provided by
Share this article
Share this article
LEXINGTON, Mass., March 15, 2021 /PRNewswire/ LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020 and provided a business update.